BioMarin Pharmaceutical

BMRNintermediary

BioMarin Pharmaceutical is a leader in rare-disease therapeutics with a portfolio of enzyme replacement therapies and the breakthrough growth drug Voxzogo for achondroplasia. Its Roctavian gene therapy for hemophilia A represents a one-time curative approach.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($2.8B)

Data statis (memuat keuangan langsung…)

Enzyme Replacement Therapies (45%)

Voxzogo (30%)

Roctavian & Other (15%)

Royalties & Collaborations (10%)

Komposisi segmen dan pelanggan utama

Detail produk

Voxzogo (vosoritide)30%

C-type natriuretic peptide analog for achondroplasia in children

Roctavian (AAV gene therapy)10%

Gene therapy for severe hemophilia A

Enzyme Replacement Therapies45%

Naglazyme, Vimizim, and Palynziq for lysosomal storage disorders and PKU

Hubungan Rantai Pasok

Pesaing

Regeneron Pharmaceuticals

Rare disease biologics

Dampak: Limited overlap in rare disease

Pfizer Inc.

Gene therapy platforms

Dampak: Competing in gene therapy

Novo Nordisk

Rare blood disorders

Dampak: Competing in hemophilia

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok BioMarin Pharmaceutical.

Info Perusahaan

Kantor Pusat

San Rafael, California, USA

Didirikan

1997

Karyawan

4,200+

Situs Web

biomarin.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor